Reply to: "A comment on `A multicenter randomized-controlled trial of nucleos(t)ide analogue cessation in HBeAg-negative chronic hepatitis B'"

J Hepatol. 2024 May;80(5):e230-e231. doi: 10.1016/j.jhep.2023.11.034. Epub 2023 Dec 16.

Authors

Florian van Bömmel¹, Thomas Berg²

Affiliations

¹ Division of Hepatology, Department of Medicine II, Leipzig University Medical Center, Liebigstrasse 20, 04103 Leipzig, Germany. Electronic address: florian.vanboemmel@medizin.uni-leipzig.de.
² Division of Hepatology, Department of Medicine II, Leipzig University Medical Center, Liebigstrasse 20, 04103 Leipzig, Germany.

PMID: 38110010
DOI: 10.1016/j.jhep.2023.11.034

No abstract available

Publication types

Letter

MeSH terms

Antiviral Agents / therapeutic use
DNA, Viral
Hepatitis B Surface Antigens
Hepatitis B e Antigens
Hepatitis B virus / genetics
Hepatitis B, Chronic* / drug therapy
Humans
Multicenter Studies as Topic
Nucleosides / therapeutic use
Randomized Controlled Trials as Topic
Treatment Outcome

Substances

Antiviral Agents
DNA, Viral
Hepatitis B e Antigens
Hepatitis B Surface Antigens
Nucleosides